RTA408 has been developed to activate NRF2 signalling, and it is being investigated in clinical trials for the treatment of patients with FRDA as a means to counteract mitochondrial dysfunction, sensitivity to oxidative stress, and impaired mitochondrial ATP production. This evidence concerns the gene NFE2L2 and Friedreich ataxia.